期刊文献+

多发性骨髓瘤患者NK细胞杀伤功能异常的研究 被引量:3

Study of NK cells dysfunction in multiple myeloma patients
原文传递
导出
摘要 目的探讨多发性骨髓瘤(MM)患者NK细胞杀伤功能下降的机制。方法以13例MM患者为研究对象,以30名健康志愿者为正常对照,采用流式细胞术检测外周血单个核细胞中CD3-CD56^+(NK细胞)表面抑制性受体(CD158a和CD158b)以及活化性受体NKG2D、NCRs(NKp30、NKp44、NKp46)的表达水平;ELISA法检测血清可溶性NKG2D配体水平;流式细胞术检测NK细胞对MM细胞株U266细胞杀伤作用的变化。结果MM患者外周血中NK细胞比例及绝对数、CD158a和CD158b表达水平与对照组比较差异无统计学意义(P值均〉0.05),两组NK细胞表面均不表达NKp44;与对照组比较,MM患者NK细胞表面活化性受体(NKG2D、NKp30和NKp46)水平均明显降低,血清中可溶性NKG2D配体水平明显升高,差异均有统计学意义(P值均〈0.05);用MM患者血清培养后的正常对照者NK细胞对U266细胞的杀伤能力较共培养前明显下降[(25.4±5.9)%对(38.5±6.5)%],差异有统计学意义(P=0.044)。结论MM患者血清可溶性NKG2D配体水平可能是导致NK细胞杀伤活性下降的原因。 Objective To explore the mechanism of NK cell dysfunction in patients with multiple myeloma (MM). Methods The expression of inhibitory receptors (CD158a and CD158b) and activating receptors NKG2D and NCRs (NKp30, NKp44 and NKp46) on CD3-CD56^+NK cell of 13 MM patients and 30 healthy controls were analyzed by flow cytometry. The concentration of soluble NKG2D ligands (MICA, MICB, ULBP1, ULBP2 and ULBP3) in serum was detected by enzyme-linked immunosorbent assay (ELISA), and the cytotoxicity of NK cell against MM cell line by flow cytometry. Results There are no significant differences of percentage and absolute number of NK cells, and the expression level of CD158a and CD158b between MM patients and healthy individuals (P〉0.05). No NKp44 expression was detected on fresh isolated NK cells from both groups. There is no difference in inhibitor receptors expression between MM patients and healthy individuals but the expression of NKG2D, NKp30 and NKp46 on NK cells were higher in MM patients as compared with that in healthy individuals. The concentration of soluble NKG2D ligands in serum was higher in MM patients as compared with that in healthy individuals (P〈0.05). Cultured healthy individual' s NK cells with MM patient' s serum could significantly decrease its cytotoxicity against MM cell line U266 cells [ (38.5±6.5)% vs (25.4±5.9)%, P= 0.044 ]. Conclusion The higher level of soluble NKG2D ligands in serum may be the mechanism of NKcell dysfunction in MM patient.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2015年第11期922-925,共4页 Chinese Journal of Hematology
基金 博士后科学基金(20110491337) 常州市卫生局重大科技项目(ZD201311) 常州市卫生局青年科技项目(QN201203) 南京医科大学重点项目(2012NJMU127)
关键词 多发性骨髓瘤 杀伤细胞 天然 受体 NK细胞凝集素样 杀伤功能 Multiple myeloma Killer cells, natural Receptors, NK cell lectin-like Cytotoxicity
  • 相关文献

参考文献18

  • 1Rollig C, Knop S, Bornhauser M. Multiple myeloma[J]. Lancet, 2015, 385(9983): 2197-2208.
  • 2Alici E, Konstantinidis KV, Sutlu T, et al. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model [J]. Exp Hematol, 2007, 35( 12): 1839-1846.
  • 3Garg TK, Szmania S, Mkhan JA, et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy[J]. Haematologica, 2012, 97(9): 1348-1356.
  • 4马玲娣,朱志超,卢绪章,蒋丽佳,周民,钱思轩,李建勇.苦参碱对K562细胞NKG2D配体表达的影响及其机制研究[J].中华血液学杂志,2014,35(5):438-442. 被引量:7
  • 5卢绪章,蔡晓辉,马铃娣,陈宝安.NKG2D介导正常人NK细胞对白血病细胞的杀伤作用[J].中华血液学杂志,2012,33(6):444-447. 被引量:5
  • 6Ashiru O, Boutet P, FernandezMessina L, et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes[J]. Cancer Res, 2010, 70(2): 481-489.
  • 7Cholujovi D, Jakubikovfi J, Kubes M, et al. Comparative study of four fluorescent probes for evaluation of natural killer cell cytotoxicity assays [ J]. Immunobiology; 2008, 213 (8): 629-640.
  • 8Frohn C, Hoppner M, Schlenke P, et al. Anti-myeloma activity of natural killer lymphocytes [J ]. Br J Haematol, 2002, 119 (3): 660-664.
  • 9King MA, Radicchi-Mastroianni MA. Natural killer cells and CD56 + T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry [J]. Cytometry, 1996, 26 (2):121-124.
  • 10Jinushi M, Vanneman M, Munshi NC, et al. MHC class I chain- related protein A antibodies and shedding are associated with the progression of multiple myeloma [J]. Proc Natl Acad Sci U S A, 2008, 105(4):1285-1290.

二级参考文献30

  • 1Obeidy P, Sharland AF. NKG2D and its ligands. Int J Biochem Cell Biol, 2009, 41 : 2364-2367.
  • 2Lu X, Kondo Y, Takamatsu H, et al. CD16 + CD56 - NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft-versus- leukemia effect. Eur J Haematol, 2008, 81 : 18-25.
  • 3Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol, 2001,22: 633-640.
  • 4Watzl C. The NKG2D receptor and its ligands-recognition beyond the "missing self" ?. Microbes Infect, 2003, 5 : 31-37.
  • 5Takamatsu H, Feng X, Chuhjo T, et al. Specific antibodies to moesin, a membrane-eytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia. Blood, 2007, 109 : 2514-2520.
  • 6Sofiani A, Zingoni A, Cerboni C, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myelo- ma cells by therapeutic agents results in enhanced NK-cell suscep- tibility and is associated with a senescent phenotype. Blood, 2009,113 : 3503-3511.
  • 7Jinushi M, Vanneman M, Munshi NC, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad SciU S A, 2008,105: 1285-1290.
  • 8Rebmann V, Schtitt P, Brandhorst D, et al. Soluble MICA as an independent prognoStic factor for the overall survival and progres- sion-free survival of multiple myeloma patients. Clin Immunol, 2007, 123: 114-120.
  • 9Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer, 2007, 110 : 943-954.
  • 10Montefusco E, Fazi F, Cordone I, et al. Molecular remission fol- lowing high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma. Leuk Lymphoma, 2001,40: 671-674.

共引文献26

同被引文献18

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部